Onyvax Ltd (London, UK) reported fi...

Onyvax Ltd (London, UK) reported findings from a cohort of 28 controls (out of 48 recruited) in its Phase 2a subject of attention of Onyvax-P, a therapeutic cancer vaccine designed to stimulate the immune regularity to seek and pull down tumor cells. Out of 26 evaluable exposes with prostate cancer who failed hormone therapy and have rising prostate specific antigen (PSA) flats 20 have shown no evidence of clinical deterioration. The

Plastisk Kirurgi Stavanger , After Hysterectomy Lose Weight